JP2001509373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001509373A5 JP2001509373A5 JP2000502082A JP2000502082A JP2001509373A5 JP 2001509373 A5 JP2001509373 A5 JP 2001509373A5 JP 2000502082 A JP2000502082 A JP 2000502082A JP 2000502082 A JP2000502082 A JP 2000502082A JP 2001509373 A5 JP2001509373 A5 JP 2001509373A5
- Authority
- JP
- Japan
- Prior art keywords
- hvem
- ltβr
- pharmaceutical composition
- binding substance
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 47
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 47
- 238000000034 method Methods 0.000 description 35
- 239000000126 substance Substances 0.000 description 27
- 230000036755 cellular response Effects 0.000 description 24
- 230000001404 mediated effect Effects 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 239000011230 binding agent Substances 0.000 description 19
- 102400001302 Gasdermin-B, N-terminal Human genes 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 208000009889 Herpes Simplex Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5196497P | 1997-07-07 | 1997-07-07 | |
| US08/898,234 | 1997-07-30 | ||
| US60/051,964 | 1997-07-30 | ||
| US08/898,234 US6140467A (en) | 1997-07-07 | 1997-07-30 | Ligand for herpes simplex virus entry mediator and methods of use |
| PCT/US1998/013897 WO1999002563A1 (en) | 1997-07-07 | 1998-07-07 | Ligand for herpes simplex virus entry mediator and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001509373A JP2001509373A (ja) | 2001-07-24 |
| JP2001509373A5 true JP2001509373A5 (cg-RX-API-DMAC7.html) | 2006-01-05 |
| JP4712966B2 JP4712966B2 (ja) | 2011-06-29 |
Family
ID=26730006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000502082A Expired - Fee Related JP4712966B2 (ja) | 1997-07-07 | 1998-07-07 | 単純ヘルペスウイルス侵入メディエーターのためのリガンドおよびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6140467A (cg-RX-API-DMAC7.html) |
| EP (1) | EP1003782B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4712966B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100620334B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN1891714B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE495240T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU741419B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2296737C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69842096D1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI222453B (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999002563A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| US6479254B2 (en) | 1996-03-22 | 2002-11-12 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II |
| US6495520B2 (en) | 1996-03-22 | 2002-12-17 | Human Genome Sciences, Inc. | Apoptosis Inducing Molecule II and methods of use |
| US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US6998108B1 (en) | 1997-07-07 | 2006-02-14 | La Jolla Institute For Allergy And Immunology | Antibodies to p30 polypeptides and methods making and using same |
| US7118742B2 (en) * | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| WO2000010591A1 (en) * | 1998-08-18 | 2000-03-02 | The Trustees Of The University Of Pennsylvania | Peptides for inhibition of herpes simplex virus entry |
| WO2001079496A2 (en) * | 2000-03-13 | 2001-10-25 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| AU2007201279B2 (en) * | 2000-03-13 | 2011-05-26 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| ATE365214T1 (de) | 2000-04-12 | 2007-07-15 | Jolla Inst Allergy Immunolog | Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen |
| WO2002032463A1 (en) * | 2000-10-18 | 2002-04-25 | Smithkline Beecham Corporation | Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules |
| US7514407B2 (en) * | 2002-03-04 | 2009-04-07 | Nymox Corporation | Spheron component peptides and pharmaceutical compositions |
| US7811983B2 (en) * | 2003-06-11 | 2010-10-12 | The University Of Chicago | Increased T-cell tumor infiltration and eradication of metastases by mutant light |
| ATE382372T1 (de) * | 2003-06-11 | 2008-01-15 | Univ Chicago | Erhöhte t-zell tumor-eindringung durch light- mutanten |
| EP2484696B1 (en) | 2006-08-28 | 2017-08-16 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic hLIGHT-specific human monoclonal antibodies |
| WO2008098183A2 (en) * | 2007-02-08 | 2008-08-14 | The University Of Chicago | Combination therapy for treating cancer |
| JP2012507299A (ja) * | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Light標的分子およびその使用 |
| GB201701194D0 (en) | 2017-01-24 | 2017-03-08 | Capella Bioscience Ltd | Antigen binding molecules that bind light |
| CN107213456B (zh) * | 2017-05-25 | 2020-08-21 | 苏州华测生物技术有限公司 | 淋巴毒素衍生物的新用途 |
| US11312781B2 (en) | 2018-01-24 | 2022-04-26 | Capella Bioscience Ltd. | Antigen binding molecules that bind LIGHT |
| WO2019238966A1 (en) * | 2018-06-15 | 2019-12-19 | Universität Bern | LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES |
| CA3173873A1 (en) | 2020-04-01 | 2021-10-07 | Avalo Therapeutics, Inc. | Methods and treatment involving excess free light |
| CN112511569B (zh) * | 2021-02-07 | 2021-05-11 | 杭州筋斗腾云科技有限公司 | 网络资源访问请求的处理方法、系统及计算机设备 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ298711B6 (cs) * | 1995-01-26 | 2008-01-02 | Biogen Idec Ma Inc. | Farmaceutické prostredky aktivující LT-beta receptor pro lécení nebo omezení pokracování, závažnosti nebo úcinku neoplazie, zpusob selekce LT-beta receptor aktivujícího cinidla a protilátky proti LT-beta receptoru |
| AU2363695A (en) * | 1995-04-27 | 1996-11-18 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
| US5654174A (en) * | 1995-07-07 | 1997-08-05 | Competitive Technologies, Inc. | Herpes simplex virus glycoprotein D variants |
| US6291207B1 (en) * | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
| EP0904278A4 (en) * | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
| US6479254B2 (en) * | 1996-03-22 | 2002-11-12 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II |
| WO1998003648A1 (en) * | 1996-07-19 | 1998-01-29 | Takeda Chemical Industries, Ltd. | Fas ligand-like protein, its production and use |
| JP4090092B2 (ja) * | 1996-07-19 | 2008-05-28 | 武田薬品工業株式会社 | 新規Fasリガンド様タンパク質およびそのDNA |
| BR9712670A (pt) * | 1996-10-25 | 1999-10-19 | Biogen Inc | Receptores para linfotoxina-beta, anticorpos anti-receptor para linfotoxina, e anticorpos antiligante de linfotoxina como agentes terapêuticos para o tratamento de doencas imunológicas |
| WO1998018824A1 (en) * | 1996-10-30 | 1998-05-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like 2 |
| JP2001524985A (ja) * | 1997-05-12 | 2001-12-04 | スミスクライン・ビーチャム・コーポレイション | ヒト腫瘍壊死因子受容体様2(tr2)抗体 |
| US6346388B1 (en) * | 1997-08-13 | 2002-02-12 | Smithkline Beecham Corporation | Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2 |
| US6051385A (en) * | 1997-10-22 | 2000-04-18 | The Regents Of The University Of Michigan | Compositions and methods for identifying and testing therapeutics against HSV infection |
| AU2972199A (en) * | 1998-02-20 | 1999-09-06 | Reinhard Ebner | Apoptosis inducing molecule ii and methods of use |
-
1997
- 1997-07-30 US US08/898,234 patent/US6140467A/en not_active Expired - Lifetime
-
1998
- 1998-07-07 TW TW087110978A patent/TWI222453B/zh not_active IP Right Cessation
- 1998-07-07 AT AT98933153T patent/ATE495240T1/de not_active IP Right Cessation
- 1998-07-07 AU AU82882/98A patent/AU741419B2/en not_active Ceased
- 1998-07-07 JP JP2000502082A patent/JP4712966B2/ja not_active Expired - Fee Related
- 1998-07-07 CA CA2296737A patent/CA2296737C/en not_active Expired - Fee Related
- 1998-07-07 EP EP98933153A patent/EP1003782B1/en not_active Expired - Lifetime
- 1998-07-07 DE DE69842096T patent/DE69842096D1/de not_active Expired - Lifetime
- 1998-07-07 CN CN2006100737047A patent/CN1891714B/zh not_active Expired - Fee Related
- 1998-07-07 WO PCT/US1998/013897 patent/WO1999002563A1/en not_active Ceased
- 1998-07-07 KR KR1020007000137A patent/KR100620334B1/ko not_active Expired - Fee Related
- 1998-07-07 CN CN98808663A patent/CN1268953A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2296737A1 (en) | Ligand for herpes simplex virus entry mediator and methods of use | |
| Sternsdorf et al. | Two Nuclear Dot‐Associated Proteins, PML and SplOO, are Often Co‐Autoimmunogenic in Patients with Primary Biliary Cirrhosis | |
| Johnson et al. | Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI | |
| Nicola et al. | Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM | |
| Diefenbach et al. | Herpes simplex virus tegument protein US11 interacts with conventional kinesin heavy chain | |
| Okazaki et al. | BHV-1 adsorption is mediated by the interaction of glycoprotein gIII with heparinlike moiety on the cell surface | |
| Wang et al. | Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells | |
| Robertson et al. | The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ (kappa) | |
| AU779461C (en) | Osteoprotegerin binding proteins and receptors | |
| CA2475604C (en) | An herpes simplex virus complex | |
| AU690601B2 (en) | Vector, viral protein, nucleotide sequence coding therefor and method for inhib iting immune recognition | |
| JP2003502283A5 (cg-RX-API-DMAC7.html) | ||
| CA2289912A1 (en) | Human receptor proteins; related reagents and methods | |
| CA2332570A1 (en) | Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine | |
| Couvineau et al. | Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29 | |
| MULLER et al. | Covalent cross‐linking of vasoactive intestinal peptide (VIP) to its receptor in intact colonic adenocarcinoma cells in culture (HT 29) | |
| FI113298B (fi) | Diagnostinen reagenssi, menetelmä ja testitarvikesarja EBV:n vasta-aineiden detektoimiseksi | |
| Lee et al. | Suppression of tetradecanoyl phorbol acetate-induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus by K1 signal transduction | |
| US6998108B1 (en) | Antibodies to p30 polypeptides and methods making and using same | |
| JP2024508088A5 (cg-RX-API-DMAC7.html) | ||
| CA2406132A1 (en) | Ligand for herpes simplex virus entry mediator and methods of use | |
| Li et al. | Glycoprotein Bb, the N-terminal subunit of bovine herpesvirus 1 gB, can bind to heparan sulfate on the surfaces of Madin-Darby bovine kidney cells | |
| WO1999020761A3 (en) | Compositions and methods for identifying and testing therapeutics against hsv infection | |
| Peng et al. | A 7-kDa protein encoded by the BamhI-H gene family of Mareks-disease virus is produced in lytically and latently infected-cells | |
| CA2404679A1 (en) | Adenine binding g-protein coupled receptors |